Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Inlexzo intravesical System |
|---|---|
| Manufacturer | Janssen Biotech, Inc |
| Prescription required | Yes |
Inlexzo intravesical System KIT 225mg(gemcitabine)
gemcitabine
Description
Inlexzo intravesical System KIT 225mg(gemcitabine) is a medicine catalog record in the MediPriceHub database. Active ingredient: gemcitabine. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Janssen Biotech, Inc. Therapeutic category: Medicine Library > Oncology Medicines > Bladder Cancer Medicines. Pack information: 225. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
INLEXZO is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.How to Use
Use gemcitabine under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: gemcitabine. Pack size: 225. Pack unit: unit. Manufacturer: Janssen Biotech, Inc. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Bladder Cancer Medicines. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Diese Angaben dienen nur als Referenz. Lassen Sie sich vor der Anwendung eines Medikaments von medizinischem Fachpersonal beraten.